@article{b2b1c97bf27343a39fd1bd99fe568bfe,
title = "Hepatitis B virus reactivation in cancer patients receiving direct-acting antivirals for hepatitis C virus infection",
keywords = "cancer, direct-acting antivirals, hepatitis B virus, hepatitis C virus, hepatitis flare, hepatology, liver enzymes, liver failure, prophylaxis, reactivation",
author = "Haley Pritchard and Hwang, {Jessica P.} and Georgios Angelidakis and Marcel Yibirin and Lan Wang and Ethan Miller and Torres, {Harrys A.}",
note = "Funding Information: Dr. Torres is or has been the principal investigator for research grants from Gilead Sciences, Inc, and Merck & Company, Inc, with all funds paid to The University of Texas MD Anderson Cancer Center. He also is or has been a paid scientific advisor for AIM Specialty Health, Dynavax Technologies, AbbVie Inc, Gilead Sciences, and Merck & Co Inc, with the terms of these arrangements are being managed by The University of Texas MD Anderson Cancer Center in accordance with its conflict‐of‐interest policies. Dr. Hwang has research grants from Gilead Sciences and Merck & Co., Inc. All other authors declare no competing interests. Funding Information: This study was supported by the National Cancer Institute under award number P30CA016672, which supports the MD Anderson Cancer Center Clinical Trials Support Resource. ",
year = "2021",
month = may,
doi = "10.1111/jvh.13478",
language = "English (US)",
volume = "28",
pages = "844--848",
journal = "Journal of Viral Hepatitis",
issn = "1352-0504",
publisher = "Wiley-Blackwell",
number = "5",
}